🍽️ oxaprozin,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Pain Relief: Oxaprozin is primarily used to relieve mild to moderate pain, including pain caused by conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and juvenile rheumatoid arthritis. It helps reduce inflammation, swelling, stiffness, and joint pain.

  2. Anti-inflammatory Effects: Like other NSAIDs, oxaprozin works by inhibiting the production of prostaglandins, which are substances in the body that contribute to inflammation and pain. By reducing inflammation, oxaprozin helps alleviate symptoms associated with inflammatory conditions.

  3. Musculoskeletal Disorders: Oxaprozin is effective in providing symptomatic relief for musculoskeletal disorders characterized by inflammation, such as tendonitis, bursitis, and sprains.

  4. Dosage and Administration: Oxaprozin is typically taken orally, usually once or twice daily with food or milk to minimize gastrointestinal side effects. The dosage and duration of treatment depend on the individual's medical condition and response to therapy.

  5. Long-term Use: Oxaprozin is usually prescribed for short-term use to relieve acute pain or for extended periods to manage chronic inflammatory conditions like arthritis. However, prolonged use of NSAIDs, including oxaprozin, may increase the risk of adverse effects.

  6. Side Effects: Common side effects of oxaprozin may include gastrointestinal symptoms such as stomach pain, heartburn, nausea, vomiting, diarrhea, and constipation. It may also cause dizziness, headache, drowsiness, fluid retention, elevated blood pressure, and allergic reactions in some individuals.

  7. Cardiovascular Risks: NSAIDs, including oxaprozin, may increase the risk of cardiovascular events such as heart attack and stroke, particularly when used at high doses or for long durations. This risk may be higher in individuals with pre-existing cardiovascular conditions or those taking other medications that affect blood clotting.

  8. Gastrointestinal Risks: Oxaprozin can cause gastrointestinal ulcers, bleeding, and perforation, which may be severe and potentially life-threatening. Older adults and individuals with a history of peptic ulcers, gastrointestinal bleeding, or other gastrointestinal disorders are at higher risk.

  9. Kidney and Liver Effects: Prolonged use of oxaprozin may lead to kidney damage, reduced kidney function, or acute kidney injury, especially in susceptible individuals. It may also cause liver toxicity or worsen pre-existing liver conditions.

  10. Drug Interactions: Oxaprozin may interact with other medications, including anticoagulants, antiplatelet drugs, corticosteroids, selective serotonin reuptake inhibitors (SSRIs), and certain blood pressure medications. These interactions can increase the risk of bleeding, gastrointestinal complications, or other adverse effects.

  11. Contraindications: Oxaprozin is contraindicated in individuals with a history of hypersensitivity reactions to NSAIDs, aspirin-sensitive asthma, peptic ulcer disease, severe kidney impairment, and active gastrointestinal bleeding.

  12. Pregnancy and Lactation: NSAIDs, including oxaprozin, should be avoided during the third trimester of pregnancy due to the risk of fetal harm and complications during delivery. They may also pass into breast milk and affect nursing infants, so caution is advised while breastfeeding.

  13. Monitoring: Regular monitoring of renal function, liver function, and blood pressure may be recommended during long-term treatment with oxaprozin to detect any potential adverse effects.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of oxaprozin,(prescription) On Probiotics

Rank Probiotic Impact
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by oxaprozin,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Coprococcus genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Segatella genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Clostridium perfringens A no rank Decreases 👶 Source Study
Clostridium perfringens D no rank Decreases 👶 Source Study
Escherichia coli O55:H7 no rank Decreases 👶 Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O126:H45 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O145:NM serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O167:H26 serotype Decreases 👶 Source Study
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O6:K2:H1 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Escherichia coli O78:H4 serotype Decreases 👶 Source Study
Coprococcus comes species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Bilophila wadsworthia species Decreases 📓 Source Study
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Mediterraneibacter gnavus species Decreases 📓 Source Study
Agathobacter rectalis species Decreases 📓 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Eggerthella lenta species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. tolerans subspecies Decreases 👶 Source Study

Impact of oxaprozin,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.3 0.3
ADHD 0.1 0.6 -5
Allergic Rhinitis (Hay Fever) 0.7 0.7
Allergies 0.3 0.8 -1.67
Allergy to milk products 0.6 0.1 5
Alzheimer's disease 0.4 1.8 -3.5
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.6 0.2 2
Ankylosing spondylitis 0.9 0.3 2
Anorexia Nervosa 0.5 -0.5
Antiphospholipid syndrome (APS) 0.2 0.3 -0.5
Asthma 0.5 0.5
Atherosclerosis 0.3 -0.3
Atrial fibrillation 0.6 0.9 -0.5
Autism 2.8 2 0.4
benign prostatic hyperplasia 0.1 0.1
Biofilm 0.5 0.5
Bipolar Disorder 0.4 0.6 -0.5
Cancer (General) 1.5 -1.5
Carcinoma 0.5 0.5
Celiac Disease 0.2 0.3 -0.5
Cerebral Palsy 0.3 0.3
Chronic Fatigue Syndrome 1.8 2.3 -0.28
Chronic Kidney Disease 0.5 0.8 -0.6
Chronic Obstructive Pulmonary Disease (COPD) 0.5 -0.5
Chronic Urticaria (Hives) 0.7 0.5 0.4
Coagulation / Micro clot triggering bacteria 0.4 0.4
Colorectal Cancer 0.4 0.1 3
Constipation 0.1 0.1
Coronary artery disease 0.4 0.5 -0.25
COVID-19 1 1.5 -0.5
Crohn's Disease 1.8 0.8 1.25
cystic fibrosis 0.4 0.4
deep vein thrombosis 0.4 0.4
Depression 1.8 3.2 -0.78
Eczema 0.4 0.3 0.33
Endometriosis 0.9 0.9
Epilepsy 0.1 0.1
Fibromyalgia 0.3 1.8 -5
Functional constipation / chronic idiopathic constipation 0.7 1.3 -0.86
gallstone disease (gsd) 0.4 0.4
Generalized anxiety disorder 0.7 0.8 -0.14
giant cell arteritis 0.3 -0.3
Gout 0.5 -0.5
Hashimoto's thyroiditis 0.3 -0.3
Hidradenitis Suppurativa 0.3 0.3
High Histamine/low DAO 1.2 1.2
hypercholesterolemia (High Cholesterol) 0.3 0.3
hyperglycemia 0.1 0.1
hypersomnia 0.3 -0.3
hypertension (High Blood Pressure 0.1 0.8 -7
Hypothyroidism 0.6 -0.6
IgA nephropathy (IgAN) 1.1 -1.1
Inflammatory Bowel Disease 0.7 1.8 -1.57
Intelligence 0.8 0.5 0.6
Irritable Bowel Syndrome 0.7 0.7
Liver Cirrhosis 1.2 1.1 0.09
Long COVID 1.8 0.9 1
Low bone mineral density 0.5 -0.5
Lung Cancer 0.1 0.1
Mast Cell Issues / mastitis 0.1 0.5 -4
ME/CFS with IBS 0.5 1 -1
ME/CFS without IBS 0.9 0.9
Metabolic Syndrome 1.8 1.1 0.64
Mood Disorders 3.2 3.3 -0.03
Multiple Sclerosis 0.5 1.8 -2.6
Neuropathy (all types) 0.1 -0.1
neuropsychiatric disorders (PANDAS, PANS) 0.2 0.2
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1 0.8 0.25
NonCeliac Gluten Sensitivity 0.1 0.1
Obesity 1.5 1.4 0.07
obsessive-compulsive disorder 0.4 1.5 -2.75
Osteoarthritis 0.7 0.7
Osteoporosis 0.5 0.5
Parkinson's Disease 1.5 1.6 -0.07
Polycystic ovary syndrome 0.4 0.3 0.33
Postural orthostatic tachycardia syndrome 0.3 0.5 -0.67
Psoriasis 0.6 1 -0.67
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 1.8 0.8 1.25
Rosacea 0.3 -0.3
Schizophrenia 1.8 0.8 1.25
scoliosis 0.5 0.3 0.67
Sjögren syndrome 0.6 0.1 5
Sleep Apnea 0.5 0.6 -0.2
Slow gastric motility / Gastroparesis 0.2 0.2
Small Intestinal Bacterial Overgrowth (SIBO) 0.2 0.2
Stress / posttraumatic stress disorder 0.6 0.7 -0.17
Systemic Lupus Erythematosus 1.3 1.3
Tic Disorder 0.5 -0.5
Type 1 Diabetes 0.9 0.3 2
Type 2 Diabetes 1.5 1.1 0.36
Ulcerative colitis 1.1 1.6 -0.45
Unhealthy Ageing 1.3 0.8 0.63
Vitiligo 1.3 -1.3

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [44.222.134 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.222.134 ]